Sosei Group Corporation
Sosei Heptares is a fully integrated biopharmaceutical company focused on bringing life-changing medicines based on world-class science to patients globally. Our vision is to become one of Japan’s global biopharmaceutical champions.
Sosei Heptares has a leading development capability and a profitable and growing commercial operation in Japan, which it intends to expand into additional selected markets in the Asia-Pacific region.
Sosei Heptares is advancing a broad and deep pipeline of novel medicines created using its world-leading GPCR-targeted StaR® technology and structure-based drug design platform across multiple therapeutic areas, including neurology, immunology, gastroenterology, and inflammatory diseases.
In addition, we have leveraged our unique discovery and development capabilities to establish multiple value-generating partnerships with world-leading biopharmaceutical companies, including AbbVie, Genentech (Roche), GSK, Lilly, Neurocrine Biosciences, Novartis, Pfizer, Sanofi and Takeda.
Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in London and Cambridge, UK. In July 2023, Sosei Heptares acquired all shares of Idorsia Pharmaceuticals Japan Ltd and Idorsia Pharmaceuticals Korea Co., Ltd from Idorsia Ltd and Idorsia Pharmaceutical Ltd.
“Sosei Heptares” is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies.
Established |
June 22, 1990 |
---|---|
Capital |
46,807 million yen (as of 31 December 2023) |
Scope of Business |
Planning strategy for the entire Group and managing subsidiary companies |
Representative Executive Officer, Chairman, President and Chief Executive Officer |
Christopher Cargill |
Securities Code |
4565-JP |
Accounting Period |
12 months ended 31 December |
Number of Employees |
350 (consolidated figure, as of end of December 2023) |
Corporate Headquarters |
PMO Hanzomon 11F |
Company Registration Number and Date |
0100-01-021288 registered on 22 June 1990 |
Sosei Group Corporation London Branch
Scope of Business |
Corporate representation in the UK |
---|---|
Address |
North West House, |
Company Registration Number and Date |
FC024112 registered on 01 April 2002 |
UK Branch Registration Number and Date |
BR006736 registered on 01 April 2002 |
VAT Number |
GB 809812124 |
Sosei Co. Ltd.
Capital |
JPY 90,000,000 |
---|---|
Scope of Business |
Drug development, manufacture and sales, and business development in Japan |
Representative Director |
Chris Cargill |
Holding Company Stake |
100% |
Address |
PMO Hanzomon 11F |
Company Registration Number and Date |
0100-01-103556 registered on 02 October 2006 |
Heptares Therapeutics Ltd.
Capital |
GBP 416,000 |
---|---|
Scope of Business |
Drug discovery based on targeting of G protein-coupled receptors |
Representative Director |
Matt Barnes |
Holding Company Stake |
100% |
Address |
Steinmetz Building, Granta Park |
Company Registration Number and Date |
06267989 registered on 04 June 2007 |
VAT Number |
GB 912562244 |
EORI Number |
GB 912562244000 |
Data Protection Registration Number and Date |
Z1055500 registered on 21 September 2007 |
Heptares Therapeutics Ireland Limited
Capital |
EUR 100 |
---|---|
Scope of Business |
Corporate representation in the EU |
Representative Director |
Chris Cargill |
Holding Company Stake |
100% by Heptares Therapeutics Ltd in UK |
Address |
c/o Byrne Wallace LLP |
Company Registration Number and Date |
656998 registered on 16 September 2019 |
Idorsia Pharmaceuticals Japan
CapitalCapital |
JPY 95,000,000 |
---|---|
Scope of Business |
Drug manufacture and sales |
Representative Director and President |
Satoshi Tanaka |
Holding Company Stake |
100% |
Address |
Midtown East, |
Company Registration Number and Date |
0100-01-190615 registered on 26 March 2018 |
Idorsia Pharmaceuticals Korea
Capital |
KWR 100 mio. |
---|---|
Scope of Business |
Drug manufacture and sales |
Representative Director and Chairman |
Satoshi Tanaka |
Holding Company Stake |
100% |
Address |
F17, 410 Teheran-Ro |
Company Registration Number and Date |
210-86-02517 registered on 7 July 2022 |